Jean-Pierre Latere founded EsoBiotec in 2021. The company was launched in stealth mode and then funded in 2022 by leading Benelux VCs such as UCB Ventures, SRIW Life Sciences, Thuja Capital and Sambrinvest.

Jean-Pierre was thoughtful from the beginning about how his board of directors should be configured, making sure that the board also includes a strong director who is independent from his key investors and has a strong CEO and science background. 

In this session Jean-Pierre is going to share the how and why.

Before EsoBiotec, Jean-Pierre served as Chief Operating Officer of Celyad Oncology where he supported transfer to clinics (Europe and USA) of autologous and allogeneic CAR T products. He started his career at Johnson & Johnson (Belgium and USA) where he worked on pharmaceuticals then on medical devices. He was Science & Technology leader at Dow Corning (Belgium & USA) serving Healthcare and Beauty Care markets.